US 12115163
Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor
granted A61KA61K31/495A61K31/502
Quick answer
US patent 12115163 (Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor) held by IDEAYA Biosciences, Inc. expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- IDEAYA Biosciences, Inc.
- Grant date
- Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K31/495, A61K31/502, A61K31/519, A61K45/06